相关实验视频

Updated: Feb 28, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

皮尔托布鲁替尼单疗在治疗先验慢性淋巴细胞白血病中的有效性:贝叶斯网络对随机对照试验的元分析

Toby A Eyre¹, Lisa M Hess², Ehsan Masoudi³

¹Oxford University Hospitals NHS Trust, London OX3 9DU, UK.

|February 27, 2026

概括

与一线慢性淋巴细胞白血病治疗中的ibrutinib相比,pirtobrutinib显示出更高的无进展生存率. 虽然可以与其他BTK抑制剂进行比较,但由于可信度间隔很大,需要进一步研究.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

慢性淋巴细胞白血病 (CLL) 有多种有效的治疗选择.
最近在2025年进行的第三期试验显示,非共价BTK抑制剂皮尔托布鲁替尼在以前未接受治疗的患者中具有积极的结果.

研究的目的:

使用贝叶斯网络元分析 (NMA) 将皮尔托布鲁丁尼与其他一线CLL治疗方法进行比较.
专注于评估BTK抑制剂 (BTKi) 单疗的整体响应率 (ORR) 和无进展生存期 (PFS).

主要方法:

系统性文献审查以确定第一线CLL相关的随机临床试验 (RCT).
贝叶斯的NMA将皮尔托布鲁替尼与国家综合癌症网络推的疗法进行比较.

主要成果:

包括八个RCT,形成两个网络. 网络1包括皮尔托布鲁丁尼布,易布鲁丁尼布和赞布鲁丁尼布.
皮尔托布鲁丁尼比易布鲁丁尼表现出更好的PFS (HR = 1.89). 赞布鲁丁尼布与皮尔托布鲁丁尼布的PFSHR为1.51.
对ORR的几率比率在皮尔托布鲁替尼和易布鲁替尼或扎努布鲁替尼之间没有显示出统计学上显著的差异.

结论:

皮尔托布鲁丁尼比伊布鲁丁尼在一线CLL中表现出改善的PFS结果.
皮尔托布鲁丁尼似乎与第二代共价BTKi单一疗法可比,尽管广泛的可信度间隔表明不确定性.
皮尔托布鲁丁尼布代表了第一线CLL治疗的有前途的未来治疗选择.

关键词:

在BTKi治疗中,BTKi疗法贝叶斯分析是贝叶斯分析.慢性淋巴细胞白血病 (CLL)作为一线治疗的第一线治疗.间接比较间接比较间接比较网络元分析网络元分析之前没有接受过治疗.

更多相关视频

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...